Capital Bank & Trust’s Haemonetics HAE Stock Holding History

Capital Bank & Trust’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-45	Closed	-$6K	–	759
2019 Q3	$6K	Buy	+45	New	+$5.71K	﹤0.01%	588

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Bank & Trust's HAE Position: Q4 2019 in Review

Capital Bank & Trust sold out of Haemonetics (HAE) in Q4 2019, closing a stake of 45 shares — an estimated $6K sold.

Capital Bank & Trust first reported a position in HAE in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 298 funds tracked by Wall St. Rank hold HAE as of Q4 2019.

Capital Bank & Trust reported no remaining Haemonetics position as of Q4 2019 after selling out during the quarter.
Capital Bank & Trust sold 45 Haemonetics shares in Q4 2019, an estimated $6K.
Capital Bank & Trust first reported a position in Haemonetics in Q3 2019 and held it in 1 quarter.
Capital Bank & Trust's Haemonetics position peaked at $6K in Q3 2019.
298 funds tracked by Wall St. Rank held Haemonetics as of Q4 2019.

Based on Capital Bank & Trust's 13F filing for Q4 2019, filed 18 Feb 2020.